Delve into the most important advances in Urologic Oncology through 10 unique masterclasses, provided by one of the world’s leading specialists in this field”

Given that Urologic Oncology is a discipline that encompasses the diagnosis and treatment of such a wide variety of urologic tumors (kidney, adrenal gland, ureter, bladder, prostate, urethra, penis, testicle...), it is to be expected that the advances in this field are not only relevant, but also substantial. Therefore, Urologic Oncology is positioned as an essential part of Urology and one of the main fields of the specialty and is closely related to Medical Oncology and Radiation Oncology. Laparoscopic Surgery, on the other hand, has become widespread and is nowadays considered the standard approach for most urologic tumors.  

TECH has created this program precisely to cover the most important novelties in the area of Urologic Oncology. All the content has been written not only from a theoretical perspective, but also from a practical one, as numerous simulated cases and real examples are included throughout the syllabus. In fact, the specialist will find 10 masterclasses made specifically for this program, in which one of the most renowned experts in the field covers all the intricacies of the topics covered in this Professional master’s degree.

A wide range of surgeries are covered throughout the syllabus, such as removal of all or part of the kidney due to cancer or benign diseases, removal of very large and complex kidney stones, reconstruction of ureteral narrowing, removal of retroperitoneal tumors, oncological and reconstructive surgery of the bladder, prostate surgery for benign diseases or cancer, treatment of urinary incontinence, removal of malignant testicular tumors, andrological surgery (testicular biopsy, penile prosthesis, etc.), among others.

The 100% online format, without in-person classes and fixed schedules, allows this program to be adapted to all kinds of schedules and responsibilities. The Virtual Campus is available 24 hours a day and can be accessed from any device with an Internet connection. Furthermore, all the content can be downloaded, so that you can manage the course workload from a smartphone, tablet or computer of your choice, whenever and however you want.

You will benefit from the practical vision of one of the most prestigious hospital environments in the field of Urologic Oncology, delving into the specificities of urologic tumor pathologies with 10 masterclasses”

This Professional master’s degree in Urologic Oncology contains the most complete and up-to-date scientific program on the market. The most important features include:

• More than 75 clinical cases presented by Urologic Oncology experts. The graphic, schematic, and practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Diagnostic-therapeutic developments on assessment, diagnosis, and treatment in Urologic Oncology
• Contains practical exercises where the self-evaluation process can be carried out to improve learning
• Iconography of clinical and diagnostic image tests
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• With special emphasis on evidence-based medicine and research methodologies in Urologic Oncology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Professional master’s degree may be the best investment you can make when selecting a refresher program for two reasons: in addition to updating your knowledge in Urologic Oncology, you will obtain a qualification from TECH Global University"

The teaching staff includes professionals from the field of urologic oncology, who contribute their experience to this academic program, as well as renowned specialists from leading scientific societies.

The multimedia content developed with the latest educational technology will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training program to train in real situations.

This program is designed around Problem-Based Learning, whereby the physician must try to solve the different professional practice situations that arise during the course. For this purpose, the physician will be assisted by an innovative interactive video system created by renowned and experienced experts in the field of Urologic Oncology with extensive teaching experience.

Increase your decision-making confidence by updating your knowledge through this Professional master’s degree"

Make the most of the opportunity to learn about the latest advances in Urologic Oncology and improve your patient care"

The structure of the contents has been designed by a team of professionals from the best hospitals and universities in the country, who are aware of the relevance of up-to-date training to be able to intervene in the prevention, diagnosis, and treatment of infection in pediatric patients, and are committed to quality teaching through new educational technologies.

This Professional master’s degree in Urologic Oncology contains the most complete and updated scientific program on the market”

Module 1. Update on Oncological Principles, Functional Sequelae and Supportive Treatment of Patients with Urological Tumors

1.1. Molecular Biology of Cancer
1.2. Prognostic Factors, Tumor Markers, and Paraneoplastic Syndromes in Urologic Oncologic Pathology
1.3. Tumor Genetics
1.4. Oncologic Emergencies in Urology
1.5. Oncological Principles: Etiology, Susceptibility, and Epidemiology
1.6. Principles of Urologic Surgical Oncology
1.7. Clinical Trials in Urologic Oncology Patients
1.8. Supportive Care of the Oncologic Patient in Urology
1.9. Genitourinary Functional Sequelae of Oncologic Treatments in Urology 

1.9.1. Surgical Andrology
1.9.2. Reconstructive Surgery

1.10. Nuclear Medicine and Molecular Imaging in Oncologic Tumor Pathology

1.10.1. Scientific Evidence in Urologic Oncology
1.10.2. New Tracers

Module 2. Advances in the Diagnosis, Treatment and Follow-Up of Non-Muscle Invasive Bladder Carcinoma

2.1. Epidemiology and Etiopathogenesis
2.2. Pathologic Anatomy/Pathogenesis

2.2.1. TNM
2.2.2. WHO
2.2.3. Biopsies/Samples
2.2.4. Risk Factors
2.2.5. Other factors: T1A-A, Lymphovascular Invasion, Variants, Markers, etc.
2.2.6. CIS

2.3. Diagnosis Part I

2.3.1. Clinical Symptoms
2.3.2. Imaging Tests
2.3.3. Urine Cytology
2.3.4. Molecular Markers (Clinical Applications to Date)

2.4. Diagnosis Part II

2.4.1. Cystoscopy
2.4.2. Photodynamic Diagnosis
2.4.3. NBI
2.4.4. Second TURP

2.5. Risk Groups

2.5.1. EORTC
2.5.2. Risk and Progression Charts; CUETO
2.5.3. CIS

2.6. Adjuvant Treatment with Chemotherapy

2.6.1. Single Dose Post-TURP
2.6.2. Adjuvant
2.6.3. Options to Increase Efficiency

2.7. Adjuvant Treatment with BCG

2.7.1. Advantages
2.7.2. Strains
2.7.3. Toxicity and Treatment
2.7.4. Dose
2.7.5. Treatment Plans

2.8. Endovesical Alternatives

2.8.1. Doxorubicin
2.8.2. Epirubicin
2.8.3. Gemcitabine
2.8.4. Thiotepa

2.9. Adjuvant Treatment of CIS
2.10. Treatment Plans in the Event of Standard Treatment Failure

2.10.1. Definition of Failure
2.10.2. After Chemotherapy
2.10.3. After BCG

2.11. Radical Cystectomy in Non-Muscle Invasive Bladder Cancer

2.11.1. Fundamentals
2.11.2. Immediate vs. Early-Onset
2.11.3. After BCG Failure

2.12. Monitoring

Module 3. Advances in the Diagnosis, Treatment and Monitoring of Muscle Invasive Bladder Carcinoma

3.1. Pathologic Anatomy/Pathogenesis

3.1.1. Regional Lymph Node
3.1.2. Lymph Node Involvement
3.1.3. Histological Variants
3.1.4. Muscle Invasion Pattern
3.1.5. Markers: p53, etc.
3.1.6. TNM

3.2. Urethral Involvement and Concomitant Prostate Cancer
3.3. Staging.

3.3.1. Local: MRI and CT
3.3.2. Lymph Node: MRI; CT; PET
3.3.3. TUS: UROTAC
3.3.4. Future: FDG-PET-CT; DCE-MRI; DWI-MRI

3.4. Radiotherapy

3.4.1. Neoadjuvant
3.4.2. Palliative
3.4.3. Adjuvant

3.5. Neoadjuvant Chemotherapy
3.6. Radical Cystectomy

3.6.1. Risk Assessment
3.6.2. Delay Time
3.6.3. Lymphadenectomy: Extent and Number
3.6.4. Urinary Diversion
3.6.5. Perioperative Complications
3.6.6. Palliative Cystectomy
3.6.7. Laparoscopic vs Robotic Surgery

3.7. Bladder Preservation Programs

3.7.1. TURBT
3.7.2. Radiotherapy
3.7.3. Chemotherapy
3.7.4. Multimodal Treatments

3.8. Neoadjuvant Chemotherapy
3.9. Metastatic Cancer

3.9.1. Poor Prognosis Factors
3.9.2. Prognostic Groups/Adverse Factors
3.9.3. Definition of Cisplatin “Ineligible”
3.9.4. Single-Agent Chemotherapy
3.9.5. Standard Cisplatin "Eligible” Patient Treatment
3.9.6. Alternative/2nd Line Treatment of Cisplatin "Eligible" Patients
3.9.7. Treating “Ineligible” Patients
3.9.8. Treating Symptomatic Patients

3.10. Monitoring

3.10.1. Treatment of Bone Metastases
3.10.2. Rescue Surgery
3.10.3. Urothelial Recurrence: Urethra and TUS

3.11. Role of Immunotherapy
3.12. Major Ongoing Clinical Trials
3.13. Particularities of Other Histologies

Module 4. Advances in the Diagnosis, Treatment, and Monitoring of Testicular Cancer 

4.1. Epidemiology and Staging
4.2. Diagnosis and Clinical Staging

4.2.1. Physical Examination
4.2.2. Doppler Ultrasound
4.2.3. Tumor Markers
4.2.4. CAT and MRI
4.2.5. FDG-PET-CAT
4.2.6. TNM

4.3. Staging

4.3.1. Risk Groups
4.3.2. Risk Factors/Prognosis

4.4. Orchiectomy

4.4.1. Indications
4.4.2. Role of Deferred Surgery
4.4.3. Conservative Surgery
4.4.4. Contralateral Biopsy

4.5. Pathological Anatomy

4.5.1. Role of Pathologist in Testicular Neoplasm Diagnosis
4.5.2. WHO 2016 Classification of Germinal Neoplasms
4.5.3. Diagnostic Algorithm for Non-Germinal Neoplasms
4.5.4. Staging

4.6. Stage I Treatment: Seminoma

4.6.1.  Monitoring
4.6.2. Radiotherapy
4.6.3. Adjuvant Chemotherapy
4.6.4. Retroperitoneal Lymphadenectimy
4.6.5. Risk-Adapted Treatment

4.7. Stage I Treatment: Non-Seminoma

4.7.1. Monitoring
4.7.2. Adjuvant Chemotherapy
4.7.3. Retroperitoneal Lymph Node Dissection
4.7.4.  Risk-Adapted Treatment

4.8. Treatment of Metastatic Germ Cell Tumors
4.9. Residual Tumor Mass
4.10. Systemic Treatment of Tumor Relapse
4.11. Monitoring
4.12. Testicular Stromal Tumors: Diagnosis, Treatment and Monitoring

Module 5. Advances in the Diagnosis, Treatment, and Monitoring of Penile Cancer 

5.1. Epidemiology, Etiology, and Risk Factors
5.2. Pathological Anatomy

5.2.1. Premalignant Lesions
5.2.2. Histological Subtypes of Carcinoma of the Penis
5.2.3. TNM
5.2.4. Prognostic Factors
5.2.5. Molecular Biology

5.3. Diagnosis and Staging

5.3.1. Clinical Symptoms
5.3.2. Physical Exploration
5.3.3. Imaging Tests: Ultrasound; MRI; CT; PET-CT-FDG

5.4. Images of Penile and Urethral Cancer
5.5. Anatomical Considerations of the Penis and Lymphatic Drainage
5.6. Treatment of Penile Cancer I: Surgical Treatment of the Primary Tumor

5.6.1. Non-Invasive Superficial Disease: CIS
5.6.2. Invasive Disease Confined to the Glans Penis: Ta/T1a
5.6.3. Invasive Disease: T1b/T2

5.6.3.1. Confined to Corpus Spongiosum
5.6.3.2. Invasion of Corpus Cavernosum

5.6.4. Invasive Urethral Disease: T3
5.6.5. Invasive Disease of Adjacent Structures: T4

5.7. Treatment of Carcinoma of the Penis II: Lymph Nodes

5.7.1. Daseler's Inguinal Anatomical Zones
5.7.2. General Considerations
5.7.3. Risk Stratification for Nodal Involvement in cN0

5.7.3.1. Monitoring
5.7.3.2. Lymph Node Staging

5.7.4. Modified Lymphadenectomy
5.7.5. Dynamic Sentinel Lymph Node Biopsy

5.7.5.1. cN1/cN2
5.7.5.2. Radical Inguinal Lymphadenectomy
5.7.5.3. Pelvic Lymphadenectomy

5.7.6. cN3
5.7.7. Controversies in Ilioinguinal Lymphadenectomy

5.8. Penile Cancer Treatment III: Radiotherapy

5.8.1. Indications

5.8.1.1. Ta/T1a
5.8.1.2. T2

5.8.2. Regional Lymph Node

5.9. Penile Cancer Treatment IV: SYSTEMIC

5.9.1. Adjuvant Chemotherapy
5.9.2. Neoadjuvant Chemotherapy
5.9.3. Palliative Chemotherapy.
5.9.4. Targeted Therapy

5.10. Monitoring

5.10.1. General Aspects
5.10.2. Clinical Guides
5.10.3. Local Recurrence
5.10.4. Regional Recurrence

5.11. Quality of Life
5.12. Primary Urethral Carcinoma

Module 6. Advances in Renal, Adrenal Gland and Retroperitoneal Carcinoma Diagnosis, Treatment, and Monitoring

6.1. Epidemiology and Etiopathogenesis
6.2. Diagnostic Imaging and Clinical Staging

6.2.1. Doppler and Contrast Ultrasound: Evaluation of Complicated Renal Cyst, Renal Mass and Dissemination
6.2.2. MRI and CT: Diagnosis, Staging and Monitoring

6.3. Pathologic Anatomy/Pathogenesis

6.3.1. WHO
6.3.2. ISUP
6.3.3. Furhman
6.3.4. Clear Cells
6.3.5. Papillary
6.3.6. Chromophobic
6.3.7. Other Histologies

6.4. Renal Tumor Biopsy

6.4.1. Technical Aspects
6.4.2. Indications
6.4.3. Side effects:
6.4.4. Efficacy
6.4.5. Cystic Lesions

6.5. Prognostic Factors

6.5.1. TNM
6.5.2. Histological Factors
6.5.3. Clinical Factors
6.5.4. Molecular Factors

6.6. Localized Renal Carcinoma

6.6.1. Monitoring
6.6.2. Radical Surgery vs. Nephron-Sparing Surgery
6.6.3. Nephron-Sparing Surgery
6.6.4. Adrenalectomy
6.6.5. Lymphadenectomy
6.6.6. Pre-Nephrectomy Embolization
6.6.7. Ablative Treatments

6.7. Advanced Localized Renal Carcinoma

6.7.1. cN+
6.7.2. Unresectable Tumors
6.7.3. IVC Thrombosis
6.7.4. Adjuvant and Neoadjuvant Treatment
6.7.5. Clinical Trials

6.8. Advanced or Metastatic Renal Carcinoma

6.8.1. The Role of Radical Nephrectomy
6.8.2. Cytoreductive Surgery + Immunotherapy
6.8.3. The Role of Metastasectomy
6.8.4. Radiotherapy
6.8.5. Embolization
6.8.6. Symptomatic Treatment of Patients with Renal Carcinoma

6.9. Systemic Treatment     

6.9.1. Chemotherapy.
6.9.2. Immunotherapy

6.9.2.1. Advances in Immunotherapy
6.9.2.2. α- IFN
6.9.2.3. IL-2
6.9.2.4. Vaccines and Targeted Immunotherapies

6.9.2.4.1. Tumor Antigen 5T4 + 1st Line Therapies
6.9.2.4.2. Anti PD-1 or PD-L1 Antibodies
6.9.3. Targeted Therapy

6.9.3.1. Advances in Targeted Therapy
6.9.3.2. IMDC Risk/Prognostic Groups: Therapeutic Implication
6.9.3.3. Tyrosine Kinase Inhibitors
6.9.3.4. Monoclonal Antibodies Against Circulating VEGF
6.9.3.5. mTOR Inhibitors

6.9.4. 1st Line Treatment: Sunitinib
6.9.5. 1st Line Treatment: Pazopanib
6.9.6. 1st Line Treatment: Other Options
6.9.7. 1st Line Treatment in Patients with Poor Prognosis: Temsirolimus
6.9.8. 1st Line Therapeutic Positioning
6.9.9. 2nd Line Treatment: Axitinib
6.9.10. 2nd Line Treatment: Everolimus
6.9.11. 2nd Line Treatment: Cabozantinib
6.9.12. 2nd Line Treatment: Nivolumab
6.9.13. 2nd Line Treatment: Subsequent Options
6.9.14. Therapeutic Sequencing in Renal Carcinoma: Treatment Positioning
6.9.15. Symptomatic Treatment of Patients with Renal Carcinoma
6.9.16. Non-Clear Cell Carcinomas

6.10. Monitoring

6.10.1. Imaging Tests
6.10.2. Recurrence: Local and Distant
6.10.3. Ablative Treatments

6.11. Drug Resistance Mechanism
6.12. Major Developments in Metastatic Kidney Cancer: Clinical Trials Underway
6.13. Suprarenal Mass

6.13.1. Differential Diagnosis
6.13.2. Functioning Mass Diagnosis
6.13.3. Surgical Management
6.13.4. Metastatic Cancer

6.14. Primary Retroperitoneal Tumors

6.14.1. Differential Diagnosis
6.14.2. Diagnostic Techniques
6.14.3. Surgical Management
6.14.4. Metastatic Cancer   

Module 7. Advances in the Diagnosis, Treatment, and Monitoring of Prostate Cancer

7.1. Epidemiology and Risk Factors
7.2. Diagnosis

7.2.1. TR
7.2.2. PSA: Density, Kinetics, Ratio, PHI, etc.
7.2.3. Other Markers: Genetic, PCA3, 4K, etc.
7.2.4. Prostate Biopsy

7.3. Screening vs. Early Diagnosis 
7.4. Diagnostic Imaging

7.4.1. Ultrasonography: Sonoelastography, Contrast, Histoscanning, etc.
7.4.2. Bone Scan
7.4.3. CAT
7.4.4. MRI
7.4.5. PET-CAT
7.4.6. mpMRI: Technical Aspects

7.5. Pathologic Anatomy/Pathogenesis

7.5.1. Biopsies
7.5.2. RP Piece

7.6. Clinical and Pathologic Staging
7.7. Deferred Treatment

7.7.1. Localized Prostate Cancer: AS vs. WW
7.7.2. Locally Advanced
7.7.3. Metastatic

7.8. Localized Prostate Cancer

7.8.1. RT: General Information

7.8.1.1. IMRT/IGRT
7.8.1.2. Dose Escalation
7.8.1.3. Hormone Therapy
7.8.1.4. RxT + CT
7.8.1.5. Dose Escalation + Hormone Therapy

7.8.2. PR: General Information

7.8.2.1. Surgical Technique: Open-Laparoscopic-Robotic
7.8.2.2. Conservation of Neurovascular Bundles

7.8.3. Focal Therapy

7.9. Radical Prostatectomy

7.9.1. Low Risk
7.9.2. Medium Risk
7.9.3. High Risk and Locally Advanced
7.9.4. Lymphadenectomy and Lymph Node Involvement
7.9.5. Adjuvant and Neoadjuvant Hormone Therapy
7.9.6. Conservation of Neurovascular Bundles: Indications and Results

7.10. Radiotherapy

7.10.1. Low Risk
7.10.2. Medium Risk
7.10.3. High Risk
7.10.4. Locally Advanced: MRC P23/PR07; TAP 32; SPCG-7/SFUO-3
7.10.5. Ganglion Chains: RTOG 85-31; UK-STAMPEDE
7.10.6. Proton Therapy
7.10.7. Low Dose Rate Brachytherapy
7.10.8. High Dose Rate Brachytherapy
7.10.9. RxT after RP: EORTC 22911; ARO; SWOG 8794
7.10.10. Nodes

7.11. Cryosurgery
7.12. HIFU
7.13. Focal Therapy

7.13.1. Negative Biopsy + Elevated PSA
7.13.2. mpMRI
7.13.3. Bio markers
7.13.4. Future
7.13.5. PI-RADS Scientific Evidence
7.13.6. Ultrasound-Guided Prostate Biopsy +MRNR

7.13.6.1. Advances in Ultrasound-Guided Prostate Biopsy
7.13.6.2. Material
7.13.6.3. Technique: Transrectal/Transperineal

7.13.7. Fusion Biopsy
7.13.8. Cognitive Biopsy
7.13.9. Scientific Evidence
7.13.10. Cost-Effectiveness of MRI in the Detection of Prostate Cancer
7.13.11. Focal Therapy: Index Lesion; Clonal Theory
7.13.12. Selection Criteria. Risk Stratification
7.13.13. Energy Sources: HIFU, Cryotherapy, Brachytherapy, Electroporation, Photodynamic Therapy, Cyberknife
7.13.14. Monitoring and Recurrence

7.14. Metastatic Prostate Cancer

7.14.1. Standard Treatment: Hormone Therapy
7.14.2. SWOG: Risk Groups
7.14.3. Intermittent Blocking

7.15. Castration Resistance: Etiology
7.16. CRPC Definition New Criteria
7.17. Clinicopathological Prognostic Factors in CRPC. Androgen Deprivation in mCPRC. Response Markers
7.18. Non-Metastatic CRPC (CRPC-M0). Clinical Management. Monitoring Criteria
7.19. Hormonal Maneuvers in CRPC. Scientific Evidence
7.20. 1st Line Chemotherapy Treatment: Docetaxel

7.20.1. mCRPC
7.20.2. CRPC

7.21. Non-1st Line Chemotherapy Treatment: Cabazitaxel. Other Drugs
7.22. Hormone Treatment in CRPC Abiraterone

7.22.1. mCRPC
7.22.2. CRPC

7.23. Hormone Treatment in CRPC Enzalutamide

7.23.1. mCRPC
7.23.2. CRPC

7.24. Treatment with Bone-Targeted Agents

7.24.1. Bisphosphonates
7.24.2. Denosumab
7.24.3. Radium-223

7.25. Immunotherapy in mCRPC
7.26. Symptomatic Treatment of CRPC Patients
7.27. CRPC Treatment Algorithm: Positioning and Sequencing
7.28. Resistance Mechanisms in CRPC Hormonal Treatment: AR-V7 and Other Related Factors
7.29. CRPC Molecular Biology: BRCA and Related Genes
7.30. CRPC Molecular Biology: Epigenetic Angiogenesis
7.31. CRPC Molecular Biology: Other Molecular Pathways Involved
7.32. Main Ongoing Clinical Trials in CRPC
7.33. Future Outlook of CRPC

A unique, key, and decisive training experience to boost your professional development"